California Democrats, labor unions, health insurers and consumer advocacy groups — along with newly joined backer Tom Steyer, the billionaire activist — are restarting their effort to shed more light on prescription drug prices after a similar measure sputtered last year.

The House will vote on the GOP's ObamaCare repeal and replace plan Thursday after nearly seven years of trying to take down the healthcare law.

Today State Senator Ricardo Lara, who recently co-introduced Californians for a Healthy California Act (SB 562), which amounts to single-payer healthcare for the state, announced that he will be running to serve as California's State Insurance Commissioner - a statewide elected office dedicated to protecting consumers, enforcing all insurance regulations, and safeguarding Californians' economic and health security.

How would a “competitive bidding process” for drugs work? We may soon find out, if President Donald Trump gets his way with the Republican healthcare bill.

Conservative House Republicans said Monday night that they have enough votes to block the GOP’s legislation to dismantle the Affordable Care Act, as House leaders proposed changes to the bill in a late effort to draw support.

In the past few months, four bills have been introduced in Congress calling for transparency in prescription drug pricing. These bills—HR 1038, HR 1316, S.3308 and, earlier this week, one called C-THRU—largely concern pharmacy benefit managers (PBMs), a heretofore largely unrecognized component of the pharmaceutical industry.